IP Library Granted Patent US 9,339,466
Granted Patent B2
US 9,339,466 · App. 13/069,813 · Granted May 17, 2016

Polymorphic forms of ST-246 and methods of preparation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,339,466
App. No.
13/069,813
Granted
May 17, 2016
Kind
B2
Abstract

Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Claims (25)

1. A polymorph Form I of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-benzamide (ST-246) which shows an X-ray powder diffraction pattern having characteristic peaks at a reflection angle 2θ of about 7.63, 10.04, 11.47, 14.73, 15.21, 15.47, 16.06, 16.67, 16.98, 18.93, 19.96, 20.52, 20.79, 22.80, 25.16, 26.53, 27.20, 27.60, 29.60, 30.23, 30.49, 30.68, 31.14, 33.65, 34.33, 35.29, 35.56, 36.30, 37.36, 38.42, 38.66 degrees.

2. An isolated polymorph according to claim 1 that is at least 70% free of other forms.

3. An isolated polymorph according to claim 1 that is at least 80% free of other forms.

4. An isolated polymorph according to claim 1 that is at least 90% free of other forms.

5. An isolated polymorph according to claim 1 that is at least 95% free of other forms.

6. An isolated polymorph according to claim 1 that is at least 99% free of other forms.

7. A pharmaceutical composition comprising the polymorph of claim 1 and further comprising one or more pharmaceutically acceptable ingredients selected from the group consisting of carriers, excipients, diluents, additives, fillers, lubricants and binders.

8. The pharmaceutical composition of claim 7 , wherein the composition is formulated for oral administration.

9. A method of producing the polymorph Form I according to claim 1 , comprising the steps of:

a) dissolving ST-246 in at least one organic solvent and an amount of water to make a solution;

b) cooling said solution to a temperature that causes the preferential crystallization of said ST-246 polymorphic Form I; and

c) optionally drying the formed crystals of ST-246,

wherein the at least one organic solvent is selected from the group consisting of isopropyl alcohol (TPA), ethyl acetate, ethanol, methanol, acetone, isopropyl acetate and tetrahydrofuran (THF).

10. The method of claim 9 further comprising adding seed crystals of polymorphic Form I ST-246 during step (b).

11. The method of claim 9 , wherein an organic solvent is methanol or THF.

12. The method of claim 9 , wherein said cooling step takes place over at least 15 minutes.

13. The method of claim 9 , wherein said cooling step takes place over at least 2 hours.

14. The method of claim 9 , wherein said cooling step takes place over at least 5 hours.

15. The method of claim 9 , wherein the at least one organic solvent is ethyl acetate.

16. The method of claim 9 , wherein the at least one organic solvent is isopropyl alcohol.

17. The method of claim 9 , wherein the at least one organic solvent is ethyl acetate and the water content is about 40% by volume of total solvent volume.

18. The method of claim 9 , wherein the at least one organic solvent is ethyl acetate and the water content is about 5% by volume of total solvent volume.

19. The method of claim 9 , wherein the at least one organic solvent is ethyl acetate and the water content is about 3% by volume of total solvent volume.

20. The method of claim 9 , wherein the at least one organic solvent is ethyl acetate and the water content is about 2% by volume of total solvent volume.

21. The method of claim 9 , wherein the at least one organic solvent is isopropyl alcohol and the water content is about 5% by volume of total solvent volume.

Assignments (3)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 40349/0219 Recorded Mar 13, 2020
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: SIGA TECHNOLOGIES, INC.
Reel/Frame 052163/0014 →
SECURITY INTEREST Recorded Nov 16, 2016
From: SIGA TECHNOLOGIES, INC.
To: CORTLAND CAPITAL MARKET SERVICES, LLC
Reel/Frame 040349/0219 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2011
From: TYAVANAGIMATT, SHANTHAKUMAR R.; STONE, MELIALANI A.C.L.; WEIMERS, WILLIAM C.; NELSON, DYLAN; BOLKEN, TOVE' C.; HRUBY, DENNIS E.; SWEETAPPLE, GARY; O'NEILL, MICHAEL H.; MCCLOUGHAN, KELLEY A.
To: SIGA TECHNOLOGIES, INC.
Reel/Frame 026006/0102 →